Format

Send to

Choose Destination
Chest. 2009 Jun;135(6):1557-1563. doi: 10.1378/chest.08-2209. Epub 2009 Mar 2.

Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.

Author information

1
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Cincinnati College of Medicine; Cincinnati, OH. Electronic address: brent.kinder@uc.edu.
2
Department of Medicine, National Jewish Medical and Research Center, Denver, CO.
3
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Cincinnati College of Medicine; Cincinnati, OH.
4
Division of Nephrology and Hypertension, Department of Medicine, University of California San Diego, San Diego, CA.
5
Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, CA.

Abstract

BACKGROUND:

Serum surfactant protein (SP) A and SP-D had prognostic value for mortality in patients with idiopathic pulmonary fibrosis (IPF) in prior studies before the reclassification of the idiopathic interstitial pneumonias. We hypothesized that baseline serum SP-A and SP-D concentrations would be independently associated with mortality among patients with biopsy-proven IPF and would improve a prediction model for mortality.

METHODS:

We evaluated the association between serum SP-A and SP-D concentrations and mortality in 82 patients with surgical lung biopsy-proven IPF. Regression models with clinical predictors alone and clinical and biomarker predictors were used to predict mortality at 1 year.

RESULTS:

After controlling for known clinical predictors of mortality, we found that each increase of 49 ng/mL (1 SD) in baseline SP-A level was associated with a 3.3-fold increased risk of mortality (adjusted hazard ratio, 3.27; 95% confidence interval, 1.49 to 7.17; adjusted p = 0.003) in the first year after presentation. We did not observe a statistically significant association between serum SP-D and mortality (adjusted hazard ratio, 2.04; p = 0.053). Regression models demonstrated a significant improvement in the 1-year mortality prediction model when serum SP-A and SP-D (area under the receiving operator curve [AROC], 0.89) were added to the clinical predictors alone (AROC, 0.79; p = 0.03).

CONCLUSIONS:

Increased serum SP-A level is a strong and independent predictor of early mortality among patients with IPF. A prediction model containing SP-A and SP-D was substantially superior to a model with clinical predictors alone.

PMID:
19255294
PMCID:
PMC2716710
DOI:
10.1378/chest.08-2209
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center